Jubilant Pharmova share price fell almost 3 percent in the early trade on July 22 after the company's Canada facility received a 'voluntary action indicated' (VAI) status from the US Food and Drug Administration (US FDA).
At 10:09am, Jubilant Pharmova was quoting at Rs 735.05, down 2.29 percent, on the BSE.
"..... wholly owned subsidiary Jubilant Pharma, announced that its subsidiary Jubilant Draximage Inc. received a communication from the USFDA through which the regulatory agency intimated that pursuant to its audit of JDI’s Radiopharmaceutical manufacturing facility at Montreal, Canada in the month of April, 2024, it has determined the inspection classification the facility as “Voluntary Action Indicated" Jubilant Pharmova said in a release.
The company had reported a multi-fold jump in consolidated net profit of Rs 481.8 crore in the quarter ended June 2024 against net profit of Rs 6 crore a year earlier.
Catch all market action in our live blog
In April 2024, its generics arm Jubilant Generics' (JGL) solid dosage manufacturing facility at Roorkee, India classified as Voluntary Action Indicated (VAI).
The share touched a 52-week high of Rs 799.95 and a 52-week low of Rs 319.30 on 19 July, 2024 and 26 October, 2023, respectively.
Currently, the stock is trading 8.53 percent below its 52-week high and 129.16 percent above its 52-week low.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
